Checkpoint Inhibitor Refractory Cancer Market Outlook, Trends And Future Opportunities (2023-2030)

Checkpoint Inhibitor Refractory Cancer Market Outlook, Trends And Future Opportunities (2023-2030)

Checkpoint Inhibitor Refractory Cancer Market, By Mechanism of Action (PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors, IDO1 Inhibitors, A2AR Inhibitors, LAG3 Inhibitors, Others), By Cancer Type (Lung Cancer, Melanoma, Renal Cell Carcinoma, Bladder Cancer, Head and Neck Cancer, Hodgkin's Lymphoma, Others), By Route of Administration (Intravenous, Oral, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) The report offers a comprehensive view of the market from supply as well as demand side to help take informed decisions.

  • Published On: Sep 2023
  • Report ID: IDA43
  • Region: Global
  • Format: PDF/EXCEL

Checkpoint Inhibitor Refractory Cancer Market Segmentation:

By Mechanism of Action

  • PD-1 Inhibitors
  • PD-L1 Inhibitors
  • CTLA-4 Inhibitors
  • IDO1 Inhibitors
  • A2AR Inhibitors
  • LAG3 Inhibitors
  • Others

By Cancer Type

  • Lung Cancer
  • Melanoma
  • Renal Cell Carcinoma
  • Bladder Cancer
  • Head and Neck Cancer
  • Hodgkin's Lymphoma
  • Others

By Route of Administration

  • Intravenous
  • Oral
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • Israel,
  • South Africa
  • North Africa
  • Central Africa
  • Rest of the Middle East

Frequently Asked Questions

The current market size of the checkpoint inhibitor refractory cancer market is estimated at USD 3.4 billion in 2023.

Increasing cancer prevalence globally, rising cases of resistance to checkpoint inhibitors, Strong R&D focus and pipeline products, Advances in combination therapies, Emergence of niche inhibitors and novel platforms, Growing diagnostic capabilities

Major players in Checkpoint Inhibitor Refractory Cancer Market: Merck, Amgen, AstraZeneca, Roche, Pfizer, Novartis, AbbVie, GlaxoSmithKline, Sanofi, Gilead Sciences, Takeda, Bristol-Myers Squibb, Merck KGaA, Regeneron, Moderna, Johnson & Johnson, Eli Lilly, Bayer, Daiichi Sankyo, Eisai

CAGR of 27.8% and market size of USD 19.1 billion by 2030